September 10, 2010 – FerroKin BioSciences has announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701. “We are excited about the potential of FBS0701 in treating […]
May 11, 2010 – CAF has been notified that a second pharmacuetical company, APP Pharmaceuticals, has begun manufacturing the generic form of the iron chelator deferoxamine mesylate. If you wish to receive the brand name form of deferoxamine (Desferal) rather than the generic form, please make sure that your doctor writes “DAW” (Dispense As Written) on […]
November 30, 2009 – FerroKin BioSciences, Inc. has announced a Phase 1B trial to study the safety and pharmacology of its new oral iron chelator, FBS0701. A total of 16 patients will be enrolled in the study at centers in the U.S., Australia and Italy. Eligibility In general, patients can qualify for […]
March 10, 2009 – CAF would like to make patients aware of a new program offered by Novartis that may reduce your Exjade prescription copayments. This program –The Exjade ScriptAssist Program – provides an opportunity for patients to save up to $900 on their Exjade prescription copayments. The Exjade ScriptAssist Program will run through May 31, […]
